Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

Vincristine 5Doxorubicin 5Cyclophosphamide 5Prednisone 4Peripheral Blood Stem Cell Transplantation 4Rituximab 3Ifosfamide 3Everolimus 3Etoposide 3Carboplatin 3romidepsin 2pembrolizumab 2fludarabine phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Lenalidomide 2Immunohistochemistry 2Gene Expression Profiling 2Cyclosporine 2Clofarabine 210-propargyl-10-deazaaminopterin 2veliparib 1prednylidene 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1etoposide phosphate 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoblastic Lymphadenopathy × pembrolizumab × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡